Sagimet Biosciences IncSGMT
Price$9.37

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$47.1MTTM through 30 Jun 2026
Free Cash Flow -$41.7MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%

Returns

-45.8%ROE
-39.7%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio45.02x
Net Debt-$113.1Mnet cash position
Cash & Equivalents$165.9M

Quality Metrics

Altman Z-Score55.31
Piotroski F-Score3 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'23
FY2023: $2M
Diluted EPS-$1.26TTM
'22'23'24'25
FY2025: $-1.58

Dividend

No dividend

Capital Allocation

R&D Spend$35M
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.